文献速递瓣膜病与结构性心脏病

无症状主动脉瓣狭窄患者心脏损伤分期预后价值研究

Staging Cardiac Damage in Patients With Asymptomatic Aortic Valve Stenosis.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

该多中心回顾性研究纳入735例无症状中重度主动脉瓣狭窄且左室射血分数保留的患者,按心脏损伤分期(0至4期)评估全因死亡率。中位随访2.6年,死亡率随分期递增:0期13%、1期25%、2期44%、3-4期58%(p<0.0001)。校正主动脉瓣置换后,分期每增加一级死亡风险增加31%(HR 1.31,95%CI 1.06-1.61,p=0.01),提示该分期系统可提供增量预后价值。

要点

  • 无症状中重度AS患者按心脏损伤分期,死亡率随分期递增(0期13%至3-4期58%)。
  • 校正主动脉瓣置换后,分期每增加一级全因死亡风险增加31%(HR 1.31)。
  • 该分期系统可能有助于识别可从择期主动脉瓣置换获益的无症状AS患者。

核心结论

  • 新的心脏损伤分期系统对无症状中重度主动脉瓣狭窄患者具有增量预后价值,可能有助于识别可从择期主动脉瓣置换获益的患者。

研究设计与样本

  • 多中心回顾性分析,纳入4个高容量中心心脏瓣膜门诊前瞻性收集的735例无症状中重度AS患者(年龄71±14岁,60%男性,主动脉瓣面积<1.5 cm2,左室射血分数≥50%)。
  • 按心脏损伤分期:0期无心脏损伤,1期左室损伤,2期左房或二尖瓣损伤,3期肺血管或三尖瓣损伤,4期右室损伤或亚临床心衰。
  • 主要终点为全因死亡率,中位随访2.6年(四分位间距1.1至5.2年)。

主要发现

  • 基线时89例(12%)为0期,200例(27%)为1期,341例(46%)为2期,105例(14%)为3或4期。
  • 死亡率随分期逐步增加:0期13%,1期25%,2期44%,3至4期58%(p<0.0001)。
  • 多变量分析校正主动脉瓣置换作为时间依赖变量后,分期与超额死亡率显著相关(每增加一级HR 1.31,95%CI 1.06-1.61,p=0.01)。
  • 分期对多个临床变量显示增量价值(净重分类指数=0.34;p=0.003)。

临床怎么用

  • 对无症状中重度AS且左室射血分数保留的患者,可采用该心脏损伤分期系统评估预后,辅助识别可能从择期主动脉瓣置换获益的高分期患者。

局限性

  • 本研究为回顾性分析,尽管数据前瞻性收集,仍需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal timing of intervention in patients with asymptomatic severe aortic stenosis (AS) remains controversial. OBJECTIVES: This multicenter study sought to test and validate the prognostic value of the staging of cardiac damage in patients with asymptomatic moderate to severe AS. METHODS: This study retrospectively analyzed the clinical, Doppler echocardiographic, and outcome data that were prospectively collected in 735 asymptomatic patients (71 ± 14 years of age; 60% men) with at least moderate AS (aortic valve area <1.5 cm2) and preserved left ventricular ejection fraction (≥50%) followed in the heart valve clinics of 4 high-volume centers. Patients were classified according to the following staging classification: no cardiac damage associated with the valve stenosis (Stage 0), left ventricular damage (Stage 1), left atrial or mitral valve damage (Stage 2), pulmonary vasculature or tricuspid valve damage (Stage 3), or right ventricular damage or subclinical heart failure (Stage 4). The primary endpoint was all-cause mortality. RESULTS: At baseline, 89 (12%) patients were classified in Stage 0, 200 (27%) in Stage 1, 341 (46%) in Stage 2, and 105 (14%) in Stage 3 or 4. Median follow-up was 2.6 years (interquartile range: 1.1 to 5.2 years). There was a stepwise increase in mortality rates according to staging: 13% in Stage 0, 25% in Stage 1, 44% in Stage 2, and 58% in Stages 3 to 4 (p < 0.0001). The staging was significantly associated with excess mortality in multivariable analysis adjusted for aortic valve replacement as a time-dependent variable (hazard ratio: 1.31 per each increase in stage; 95% CI: 1.06 to 1.61; p = 0.01), and showed incremental value to several clinical variables (net reclassification index = 0.34; p = 0.003). CONCLUSIONS: The new staging system characterizing the extra-aortic valve cardiac damage provides incremental prognostic value in patients with asymptomatic moderate to severe AS. This staging classification may be helpful to identify asymptomatic AS patients who may benefit from elective aortic valve replacement.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Tastet L, Tribouilloy C, Maréchaux S, et al. Staging Cardiac Damage in Patients With Asymptomatic Aortic Valve Stenosis. J Am Coll Cardiol. 2019. PMID: 31345430. doi:10.1016/j.jacc.2019.04.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。